COPD: Journal of Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) - Global Market Insights, Epidemiology, Drugs, Pipeline & Development Activities, Reimbursement Scenario, KOL Views, and Competitive Intelligence to 2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 25, 2022
Health, General Health, Comprehension, Therapy, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chronic obstructive pulmonary disease, Diagnosis, Awareness, Epidemiology, Clinical trial, PESTLE, Disease, SWOT, Table, Acquisition, Growth–share matrix, Competition, News, SME, COPD, Technology, Porter Novelli, Research, Lists of people executed in the United States, Dentistry, Poultry, Pharmaceutical industry, Health insurance, Medical device, Phase II

The "Chronic Obstructive Pulmonary Disease (COPD) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease (COPD) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • The Chronic Obstructive Pulmonary Disease (COPD) market report provides current treatment practices, emerging drugs, Chronic Obstructive Pulmonary Disease (COPD) market share of the individual therapies, current and forecasted Chronic Obstructive Pulmonary Disease (COPD) market size from 2019 to 2032 segmented by seven major markets.
  • The Chronic Obstructive Pulmonary Disease (COPD) epidemiology division provide insights about historical and current Chronic Obstructive Pulmonary Disease (COPD) patient pool and forecasted trend for every seven major countries.
  • Drug chapter segment of the Chronic Obstructive Pulmonary Disease (COPD) report encloses the detailed analysis of Chronic Obstructive Pulmonary Disease (COPD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

Telehealth Market size to grow by USD 109.98 billion| Increasing Cases of Chronic Diseases as Key Driver | Technavio

Retrieved on: 
Saturday, February 12, 2022
Asthma, Chronic obstructive pulmonary disease, Collection, Adoption, Patient, Cancer, Time, Health, Prevalence, Degenerative disease, Solution, CVD, COPD: Journal of Chronic Obstructive Pulmonary Disease, Driver, Conditional sentence, Confidentiality, Diabetes, USD, Hospital, Privacy, Public health, Growth, Teen Driver Challenge, FREE, Telehealth, Alzheimer's disease, Marketing

The regional growth is mainly attributed to the increasing incidences of chronic diseases such as cancer and cardiovascular diseases (CVDs), adoption of advanced technologies in telehealth, increasing healthcare expenditure, and the presence of many prominent vendors.

Key Points: 
  • The regional growth is mainly attributed to the increasing incidences of chronic diseases such as cancer and cardiovascular diseases (CVDs), adoption of advanced technologies in telehealth, increasing healthcare expenditure, and the presence of many prominent vendors.
  • The telehealth market in Europe will grow at a significant rate during the forecast period owing to various factors such as the increasing prevalence of chronic diseases, increasing technological advancements, rising healthcare expenditure, and the presence of prominent vendors in the region.
  • The region is likely to contribute to 34% of the total telehealth market growth contribution during the forecast period.
  • Key Market Drivers & Challenges:
    Increasing cases of chronic diseases is one of the key drivers influencing the market positively during the forecast period.

Worldwide Chronic Obstructive Pulmonary Disease Industry to 2030 - Market Insights, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, August 30, 2021
Health, General Health, COPD: Journal of Chronic Obstructive Pulmonary Disease, Male, Population, SWOT, Research, Epidemiology, Female, Chronic obstructive pulmonary disease, Prevalence, COPD, MOA, Review, Report, III, USD, ROA, Vaccine, Dentistry, Health insurance, Coal, Pharmaceutical industry

The "Chronic Obstructive Pulmonary Disease (COPD) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease (COPD) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The Chronic Obstructive Pulmonary Disease (COPD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Chronic Obstructive Pulmonary Disease (COPD) market size from 2018 to 2030.
  • The launch of emerging therapies will significantly impact the Chronic Obstructive Pulmonary Disease (COPD) market.

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 26, 2021
Health, Other Health, COPD: Journal of Chronic Obstructive Pulmonary Disease, Population, Male, Epidemiology, Female, Chronic obstructive pulmonary disease, Prevalence, COPD, Profile, United Kingdom, Signs and symptoms, GOLD, Vaccine, Dentistry, Medical imaging, Health insurance

The "Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology forecast - 2030" drug pipeline report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology forecast - 2030" drug pipeline report has been added to ResearchAndMarkets.com's offering.
  • This 'Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Gender-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Age-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation, and Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Chronic Obstructive Pulmonary Disease (COPD) during the forecast period (2021-2030)?

Metabolomic Profiling of Chronic Obstructive Pulmonary Disease

Retrieved on: 
Tuesday, August 3, 2021
Chronic lower respiratory diseases, Pulmonology, Health, Medicine, Chronic obstructive pulmonary disease, Obstructive lung disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chronic condition, Global Initiative for Chronic Obstructive Lung Disease, Pulmonary disease, chronic obstructive, severe early-onset

Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterized by a blockage of airflow from the lungs.COPD is associated with long-term exposure to irritating gases or particulate matter, most often from cigarette smoke and environmental pollution.

Key Points: 
  • Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterized by a blockage of airflow from the lungs.COPD is associated with long-term exposure to irritating gases or particulate matter, most often from cigarette smoke and environmental pollution.
  • While there is no cure, disease progression can be delayed by reducing exposure to pollutants and infections.The development of new therapies for delaying disease progression requires a better understanding of the pathogenesis of the COPD.Recent studies have implicated alterations in energy metabolism in numerous chronic diseases including COPD.
  • Nonetheless, a detailed analysis of metabolites, or small molecules, generated during energy production in COPD patients is not available.
  • In this study, Dr. Sun and colleagues used metabolomic profiling to investigate aerobic and anaerobic energy metabolism in COPD patients.COPD patients had a significant increase in anaerobic metabolites at rest when compared to normal subjects.Patients with higher GOLD (Global Initiative for Chronic Obstructive Lung Disease) classification levels had more severe disease, higher pyruvate and lactic acid levels, and a reduced efficiency energy supply.

Olympus Makes SeleCT™ QCT Analysis Available Nationwide via the Nuance AI Marketplace to Increase Access to Spiration Valve System Therapy

Retrieved on: 
Tuesday, July 27, 2021
Health, Chronic obstructive pulmonary disease, Health care, COPD: Journal of Chronic Obstructive Pulmonary Disease, Electronic health record, Respiratory disease, Bronchoscopic Lung Volume Reduction

The new service will also provide an option for SeleCT analysis results to be sent to a health system's electronic health record (EHR) for easier referring physician access.

Key Points: 
  • The new service will also provide an option for SeleCT analysis results to be sent to a health system's electronic health record (EHR) for easier referring physician access.
  • "1
    "Our collaboration with Nuance and Olympus advances our mission to add value and help deliver better patient care," said Dave Hannes, CEO, Imbio.
  • For more information on SeleCT Connect or to start using the service, Spiration Valve System customers can contact their Olympus representative.
  • Olympus offers the SeleCT QCT analysis service to evaluate patient eligibility for treatment with the Spiration Valve System, an FDA-designated breakthrough device to treat severe emphysema, a form of chronic obstructive pulmonary disease (COPD).

Emphysema Foundation of America and Olympus Collaborate on Virtual Lung Health Education Series

Retrieved on: 
Thursday, July 15, 2021
Pulmonology, Health, Respiratory therapy, Chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Respiratory disease, Obstructive lung disease, COPD Awareness Month

LOS ANGELES and CENTER VALLEY, Pa., July 15, 2021 /PRNewswire/ --The Emphysema Foundation of America (EFA) and medical device corporation Olympus Corporation of the Americas will partner in providing a virtual lung health education series on chronic obstructive pulmonary disease (COPD).

Key Points: 
  • LOS ANGELES and CENTER VALLEY, Pa., July 15, 2021 /PRNewswire/ --The Emphysema Foundation of America (EFA) and medical device corporation Olympus Corporation of the Americas will partner in providing a virtual lung health education series on chronic obstructive pulmonary disease (COPD).
  • The series will feature five free virtual workshops to educate COPD patients, caregivers of COPD patients, and health care providers.
  • "The Emphysema Foundation of America is proud to serve those individuals and families suffering with emphysema and COPD," said Carrel.
  • Olympus Corporation of the Americas is headquartered in Center Valley, Pennsylvania, USA, with 5,500 employees throughout North and South America.

COPD Foundation Journal Receives High Ranking

Retrieved on: 
Tuesday, July 6, 2021
Health, Other Science, General Health, Research, Pharmaceutical, Science, Chronic lower respiratory diseases, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chronic obstructive pulmonary disease, John W. Walsh, Health, Medical specialties, British Lung Foundation, Ravi Kalhan

Last week, with receipt of its first impact factor, the peer-reviewed Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (JCOPDF) became the highest-ranked COPD-focused journal among respiratory journals, according to Clarivates June 30, 2021, Journal Citation Report for 2020.

Key Points: 
  • Last week, with receipt of its first impact factor, the peer-reviewed Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (JCOPDF) became the highest-ranked COPD-focused journal among respiratory journals, according to Clarivates June 30, 2021, Journal Citation Report for 2020.
  • The impact factor calculates how often articles published in the journal in 2018 and 2019 were cited in other published research articles in 2020.
  • Our journal is only seven years old, launched in 2014 by founding Editor in Chief James D. Crapo, MD, and the COPD Foundations founder, the late John W. Walsh.
  • For a non-profit foundation to publish a medical journal is no small feat, particularly in these times of large, multi-faceted, competing publishing conglomerates, said Ruth Tal-Singer, PhD, President and Chief Scientific Officer of the COPD Foundation.

Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026: Triple Therapies will Drive Modest Growth of the COPD Market - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Pharmaceutical, Health, Cardiology, Respiratory diseases, Health, Respiratory therapy, Chronic lower respiratory diseases, Muscarinic antagonists, Asthma, Chronic obstructive pulmonary disease, Long-acting beta-adrenoceptor agonist, Shortness of breath, Inhaler, Lung, COPD: Journal of Chronic Obstructive Pulmonary Disease, Respiratory diseases, Health, Respiratory therapy, Chronic lower respiratory diseases, Muscarinic antagonists, Asthma, Chronic obstructive pulmonary disease, Long-acting beta-adrenoceptor agonist, Shortness of breath, Inhaler, Lung, COPD: Journal of Chronic Obstructive Pulmonary Disease

The "Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Chronic obstructive pulmonary disease (COPD) is defined by persistent airflow limitation (reduction in the ability to exhale at a normal rate and volume).
  • While chronic and progressive dyspnea (shortness of breath) is a key symptom, patients may also present with productive cough.
  • Triple inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) fixed-dose combination therapies delivered through a single inhaler bring convenience to more severe patients.

Hangzhou Chance Pharmaceuticals Announces NMPA Acceptance of Marketing Authorization Application for CXF11

Retrieved on: 
Friday, July 2, 2021
Respiratory diseases, Chemical compounds, Pulmonology, Chronic lower respiratory diseases, Muscarinic antagonists, Bromides, Epoxides, Thiophenes, Tiotropium bromide, Chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Bronchospasm

HANGZHOU, China, July 02, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (Chance), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing transformative inhalation therapies for the worlds most debilitating diseases, announced that the National Medical Products Administration (NMPA) of China has accepted its Marketing Authorization Application for CXF11 for the treatment of chronic obstructive pulmonary disease (COPD).

Key Points: 
  • HANGZHOU, China, July 02, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (Chance), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing transformative inhalation therapies for the worlds most debilitating diseases, announced that the National Medical Products Administration (NMPA) of China has accepted its Marketing Authorization Application for CXF11 for the treatment of chronic obstructive pulmonary disease (COPD).
  • The NMPA Acceptance of Marketing Authorization Application for CXF11is the first important milestone in product development for Chance.
  • CXF11 is Chances tiotropium bromide inhalation drug intended for prevention of bronchospasm in adults with chronic obstructive pulmonary disease (COPD).
  • Chance Pharmaceuticals is a clinical-stage biotechnology company focusing on discovering, developing and commercializing transformative inhalation therapies for the worlds most debilitating diseases.